Carrier screening, once thought to be a test primarily for specific ethnic groups, is now often recommended for every patient. The American Congress of Obstetricians and Gynecologists (ACOG) recently updated its recommendations, stating that carrier screening for spinal muscular atrophy (SMA), in addition to cystic fibrosis (CF), "should be offered to all women who are considering pregnancy or are currently pregnant."1
Inheritest® provides carrier screening for more than 500 genes that can cause cognitive or physical impairment and/or require surgical or medical intervention.
Selected to focus on severe disorders of childhood-onset, and to meet ACOG and the American College of Medical Genetics and Genomics (ACMG) criteria, many of the disorders share a recommendation for early intervention.
Inheritest® Carrier Screen offers a fast turnaround time for a complete and final fragile X result with both CGG and AGG repeats reported.
Inheritest® Carrier Screen lab report
including a final CGG/AGG fragile X result
AGG analysis in women who have a premutation with 55-90 CGG repeats provides a more accurate risk assessment compared to CGG testing alone.2-4 And with our unique, integrated approach, this combined CGG/AGG fragile X result is available without extending turnaround time, providing you and your patients with one timely and more refined risk estimate.
Carrier Screening for Genetic Conditions. Committee Opinion No. 691. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;129:e41–55.